Page last updated: 2024-12-04

benzamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

benzamide : An aromatic amide that consists of benzene bearing a single carboxamido substituent. The parent of the class of benzamides. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2331
CHEMBL ID267373
CHEBI ID28179
SCHEMBL ID16352
MeSH IDM0113868

Synonyms (105)

Synonym
benzoic acid amide
benzoylamide
nsc-3114
wln: zvr
phenylcarboxyamide
nsc3114
amid kyseliny benzoove
MLS000069472
smr000059089
phenyl carboxyamide
EU-0100160
lopac-b-2009
NCGC00015142-01
LOPAC0_000160
benzoic acid,amide
inchi=1/c7h7no/c8-7(9)6-4-2-1-3-5-6/h1-5h,(h2,8,9
NCGC00091355-01
einecs 200-227-7
nsc 3114
ai3-01031
amid kyseliny benzoove [czech]
ccris 4594
brn 0385876
hsdb 6360
C09815
benzamide
55-21-0
benzamide, zone-refined, purified by sublimation, 99.9%
benzamide, 99%
benzamide, purified by sublimation, >=99.5%
phc(=o)nh2
phc(o)nh2
benzenecarboxamide
phenylcarboxamide
CHEBI:28179 ,
NCGC00091355-02
NCGC00091355-03
STK069333
NCGC00015142-03
B 2009
B0220
B0012
B1418
NCGC00015142-05
AKOS000118773
CHEMBL267373 ,
bdbm50106187
BMSE000668
phenylamide
HMS3260O22
dtxcid101709
NCGC00258175-01
cas-55-21-0
tox21_200621
dtxsid0021709 ,
A830526
CCG-204255
HMS2231M11
S4715
NCGC00015142-04
NCGC00015142-02
NCGC00015142-06
6x80438640 ,
4-09-00-00725 (beilstein handbook reference)
unii-6x80438640
FT-0622631
FT-0622630
LP00160
benzamide [mi]
benzamide [hsdb]
HMS3371I16
BP-21224
SCHEMBL16352
NCGC00260845-01
tox21_500160
benzene carboximidoic acid
benzene carboxamide
n-benzoylamine
benzoyl nitrogen
YSKVTRZUSMWAQJ-UHFFFAOYSA-N
F3145-2903
mfcd00007968
benzamide, purum, >=98.0% (hplc)
benzamide (acd/name 4.0)
benzamide, vetec(tm) reagent grade, 98%
benzamide, p.a., 98.0%
CS-Z0019
sr-01000075601
SR-01000075601-1
benzimide
Q417731
sulfabenzamide|sulfabenzid|sulfabenzide|sulfabenzoylamide|n-sulfamylbenzamide
DS-17194
EN300-15618
SDCCGSBI-0050148.P002
NCGC00015142-07
HMS3885L18
D70176
benzene-carboxamide
benzeneamide
SY047098
HY-Z0283
55738-52-8
benzoylamine
Z33546506

Research Excerpts

Treatment

Benzamide treatment (10 mm) inhibited telomerase activity in a time-dependent manner. Treatment with benzamide to inhibit ADP-ribosylation and strand break repair increased apoptosis; splitting the dose of radiation to allow increased time for DNA repair decreased apoptosis.

ExcerptReferenceRelevance
"Benzamide treatment alone increased nuclear fragmentation in dose (2.5-10 mM) and time (4-48 h)-dependent manner."( Induction of apoptosis by benzamide and its inhibition by aurin tricarboxylic acid (ATA) in Chinese hamster V79 cells.
Bhattacharyya, NP; Dutta, J; Ghosh, U; Pandit, B, 2004
)
1.34
"Benzamide treatment (10 mm) inhibited telomerase activity in a time-dependent manner."( Benzamide and 4-amino 1,8 naphthalimide treatment inhibit telomerase activity by down-regulating the expression of telomerase associated protein and inhibiting the poly(ADP-ribosyl)ation of telomerase reverse transcriptase in cultured cells.
Bhattacharyya, NP; Ghosh, U, 2005
)
2.49
"Benzamide treatment reversed the effect of UVC-irradiation in LY-S cells and did not change the response pattern of chromatin from LY-R cells or unirradiated LY-S cells."( Benzamide-inhibitable alterations in spectral properties of chromatin accompany DNA repair in UVC-exposed L5178Y cells.
Buraczewska, I; Kleczkowska, HE; Szumiel, I, 1988
)
2.44
"Posttreatment with benzamide also attenuated MPTP neurotoxicity in mice."( Poly(ADP-ribose)polymerase inhibitor can attenuate the neuronal death after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.
Araki, T; Kato, H; Kuroiwa, H; Tsukada, T; Uchida, H; Yokoyama, H, 2010
)
0.68
"Treatment with benzamide to inhibit ADP-ribosylation and strand break repair increased apoptosis; splitting the dose of radiation to allow increased time for DNA repair decreased apoptosis."( Response of postmitotic neurons to X-irradiation: implications for the role of DNA damage in neuronal apoptosis.
Bellinzona, M; Chan, PH; Fike, JR; Gobbel, GT; Gupta, N; Vogt, AR, 1998
)
0.64

Toxicity

ExcerptReferenceRelevance
" Cerebellar granule cells at 12 days in culture when treated with a toxic dose of glutamate (100 microM) showed a rapid and transient increase of polyADP-ribose immunoreactivity."( Poly(ADP-ribose) polymerase: early involvement in glutamate-induced neurotoxicity in cultured cerebellar granule cells.
Cosi, C; Facci, L; Kanai, Y; Menegazzi, M; Milani, D; Skaper, SD; Suzuki, H; Vantini, G, 1994
)
0.29
" The neuropeptide vasoactive intestinal peptide and inhibitors of poly(ADP-ribose) polymerase also prevented this injury, but without inhibiting NO synthesis, both acting by inhibiting a toxic action of NO that is critical to tissue injury."( Excitotoxicity in the lung: N-methyl-D-aspartate-induced, nitric oxide-dependent, pulmonary edema is attenuated by vasoactive intestinal peptide and by inhibitors of poly(ADP-ribose) polymerase.
Berisha, HI; Pakbaz, H; Said, SI, 1996
)
0.29
" We conclude that exposures to toxic levels of NO cause prolonged disruption of [Ca2+]i homeostatic mechanisms, and that the resulting persistent [Ca2+]i elevations contribute to the delayed neurotoxicity of NO."( Disrupted [Ca2+]i homeostasis contributes to the toxicity of nitric oxide in cultured hippocampal neurons.
Brorson, JR; Zhang, H, 1997
)
0.3

Pharmacokinetics

ExcerptReferenceRelevance
"The clinical development of FtsZ-targeting benzamide compounds like PC190723 has been limited by poor drug-like and pharmacokinetic properties."( TXA709, an FtsZ-Targeting Benzamide Prodrug with Improved Pharmacokinetics and Enhanced In Vivo Efficacy against Methicillin-Resistant Staphylococcus aureus.
Kaul, M; LaVoie, EJ; Lyu, YL; Mark, L; Parhi, AK; Pawlak, J; Pilch, DS; Saravolatz, LD; Saravolatz, S; Weinstein, MP; Zhang, Y, 2015
)
0.98

Compound-Compound Interactions

ExcerptReferenceRelevance
"The potential for drug-drug interactions in psychiatry and patients with epilepsy is very high."( Antiepileptic-antipsychotic drug interactions: a critical review of the evidence.
Monaco, F; Mula, M,
)
0.13

Bioavailability

ExcerptReferenceRelevance
"Structure-activity studies on lead cyclobutenedione 3 led to the discovery of 4 (SCH 527123), a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist with excellent cell-based activity."( Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist.
Aki, C; Baldwin, J; Bian, H; Biju, P; Bond, R; Chao, J; Dwyer, MP; Fan, X; Fine, J; Fossetta, J; Girijavallabhan, V; Gonsiorek, W; Hipkin, RW; Jakway, J; Kaiser, B; Li, G; Lundell, D; Mayer-Ezel, R; Merritt, JR; Ozgur, L; Rindgen, D; Rokosz, LL; Stauffer, T; Taveras, AG; Terminelli, C; Wang, W; Yu, Y, 2006
)
0.54
" In addition, YH-GKA exhibited high bioavailability and moderate elimination in preclinical species."( Discovery of a novel phenylethyl benzamide glucokinase activator for the treatment of type 2 diabetes mellitus.
Choi, HH; Chong, W; Han, T; Kim, YH; Lee, BM; Lee, CH; Lee, DH; Park, K; Yi, W, 2013
)
0.67

Dosage Studied

ExcerptRelevanceReference
" Increases in cocaine dose attenuated the effects of the DA antagonists, resulting in rightward shifts of the cocaine dose-response curves."( The effects of benzamide analogues on cocaine self-administration in rhesus monkeys.
Green, KL; Luedtke, RR; Mach, RH; Nader, MA, 1999
)
0.66
" This produced a dosage form with a high intraparticulate porosity in the dry state."( Tablet and capsule hydrophilic matrices based on heterodisperse polysaccharides having porosity-independent in vitro release profiles.
Kelly, ML; Staniforth, JN; Tobyn, MJ, 2000
)
0.31
"A multiple schedule was used to evaluate the effects of changes in the magnitude of food reinforcement on the self-administration cocaine dose-response curve and on the behavioral potency of a dopamine receptor antagonist to decrease food- and cocaine-maintained responding."( Cocaine- and food-maintained responding under a multiple schedule in rhesus monkeys: environmental context and the effects of a dopamine antagonist.
Mach, RH; Morgan, D; Nader, MA; Sinnott, RS, 2002
)
0.31
" After completion of cocaine dose-response curves, the effects of the dopamine D(2)/D(3) receptor antagonist 2,3-dimethoxy-N-(9-p-fluorobenzyl)-azabicyclo[3."( Cocaine- and food-maintained responding under a multiple schedule in rhesus monkeys: environmental context and the effects of a dopamine antagonist.
Mach, RH; Morgan, D; Nader, MA; Sinnott, RS, 2002
)
0.31
" More importantly, even millimolar concentrations of CX516 did not influence the dose-response relation for CX546, suggesting the possibility that they bind to different sites."( Benzamide-type AMPA receptor modulators form two subfamilies with distinct modes of action.
Arai, AC; Kessler, M; Lynch, G; Rogers, G; Xia, YF, 2002
)
1.76
" Through modification of our initial lead 5, we have identified potent and selective 11beta-HSD1 inhibitors, such as 11n, which demonstrated improved glycemic control, decreased serum lipids, and enhanced insulin sensitivity when dosed ip in diabetic ob/ob mice."( 4-(Phenylsulfonamidomethyl)benzamides as potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1 with efficacy in diabetic ob/ob mice.
Chen, J; Du, L; Feng, Y; Leng, Y; Shen, J; Yang, H; Zhang, X; Zhou, Z, 2009
)
0.65
" We wish to disclose the discovery of a macrocycle which showed impressive biomarker activity 24-h post dosing and which demonstrated prolonged exposure in tumors."( Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model.
Bloom, JD; Boschelli, F; Dushin, RG; Golas, JM; Johnson, M; Levin, JI; Li, Z; Liu, H; Lucas, J; Nikitenko, A; Nittoli, T; Olland, A; Otteng, M; Vogan, E; Zapf, CW, 2011
)
0.64
" time profiles for several doses were explored and doses with a wide range of fluctuation in RO over the dosing interval could be identified."( Prediction of H3 receptor occupancy diurnal fluctuations using population modeling and simulation with focus on guiding dose selection in a Phase IIa study.
Boström, E; Brynne, N; Cheng, YF; Segerdahl, M, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzamides
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (42)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.89130.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency50.01780.004023.8416100.0000AID485290
Chain A, Beta-lactamaseEscherichia coli K-12Potency0.63100.044717.8581100.0000AID485294
Chain A, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID886
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency10.00000.125919.1169125.8920AID2353
endonuclease IVEscherichia coliPotency1.25890.707912.432431.6228AID1708
thioredoxin reductaseRattus norvegicus (Norway rat)Potency5.97280.100020.879379.4328AID588453
Microtubule-associated protein tauHomo sapiens (human)Potency3.16230.180013.557439.8107AID1468
thyroid stimulating hormone receptorHomo sapiens (human)Potency1.25890.001318.074339.8107AID926; AID938
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency69.42750.003041.611522,387.1992AID1159552
arylsulfatase AHomo sapiens (human)Potency1.69441.069113.955137.9330AID720538
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00280.540617.639296.1227AID2364; AID2528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency95.283423.934123.934123.9341AID1967
cytochrome P450 2C19 precursorHomo sapiens (human)Potency0.25120.00255.840031.6228AID899
chromobox protein homolog 1Homo sapiens (human)Potency63.09570.006026.168889.1251AID540317
DNA polymerase betaHomo sapiens (human)Potency79.43280.022421.010289.1251AID485314
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency0.22390.075215.225339.8107AID485360
gemininHomo sapiens (human)Potency0.10630.004611.374133.4983AID624296; AID624297
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency0.00500.031610.279239.8107AID884; AID885
M-phase phosphoprotein 8Homo sapiens (human)Potency39.81070.177824.735279.4328AID488949
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency0.00501.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency0.00501.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency0.00501.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency0.00501.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency0.00501.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency0.00501.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency0.00501.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency0.00501.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency0.00501.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency0.00501.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency0.00501.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency0.00501.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency0.00501.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency0.00501.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency0.00501.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency0.00501.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Coagulation factor VIIHomo sapiens (human)Ki49,000.00000.00021.55669.0000AID1201284; AID1325941
Poly [ADP-ribose] polymerase 1Homo sapiens (human)IC50 (µMol)15.80000.00020.81239.8100AID154621; AID162395; AID610957
Poly(ADP-ribose) glycohydrolaseHomo sapiens (human)IC50 (µMol)1,000.00000.12000.12000.1200AID610958
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (98)

Processvia Protein(s)Taxonomy
response to hypoxiaCoagulation factor VIIHomo sapiens (human)
positive regulation of leukocyte chemotaxisCoagulation factor VIIHomo sapiens (human)
blood coagulationCoagulation factor VIIHomo sapiens (human)
circadian rhythmCoagulation factor VIIHomo sapiens (human)
response to carbon dioxideCoagulation factor VIIHomo sapiens (human)
positive regulation of platelet-derived growth factor receptor signaling pathwayCoagulation factor VIIHomo sapiens (human)
protein processingCoagulation factor VIIHomo sapiens (human)
positive regulation of blood coagulationCoagulation factor VIIHomo sapiens (human)
positive regulation of cell migrationCoagulation factor VIIHomo sapiens (human)
animal organ regenerationCoagulation factor VIIHomo sapiens (human)
positive regulation of TOR signalingCoagulation factor VIIHomo sapiens (human)
response to estradiolCoagulation factor VIIHomo sapiens (human)
response to vitamin KCoagulation factor VIIHomo sapiens (human)
response to genisteinCoagulation factor VIIHomo sapiens (human)
response to estrogenCoagulation factor VIIHomo sapiens (human)
positive regulation of positive chemotaxisCoagulation factor VIIHomo sapiens (human)
response to growth hormoneCoagulation factor VIIHomo sapiens (human)
response to cholesterolCoagulation factor VIIHomo sapiens (human)
response to thyroxineCoagulation factor VIIHomo sapiens (human)
response to Thyroid stimulating hormoneCoagulation factor VIIHomo sapiens (human)
response to 2,3,7,8-tetrachlorodibenzodioxineCoagulation factor VIIHomo sapiens (human)
response to astaxanthinCoagulation factor VIIHomo sapiens (human)
response to thyrotropin-releasing hormoneCoagulation factor VIIHomo sapiens (human)
DNA damage responsePoly [ADP-ribose] polymerase 1Homo sapiens (human)
mitochondrion organizationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
mitochondrial DNA metabolic processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
regulation of protein localizationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to oxidative stressPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein modification processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
mitochondrial DNA repairPoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIPoly [ADP-ribose] polymerase 1Homo sapiens (human)
telomere maintenancePoly [ADP-ribose] polymerase 1Homo sapiens (human)
DNA repairPoly [ADP-ribose] polymerase 1Homo sapiens (human)
double-strand break repairPoly [ADP-ribose] polymerase 1Homo sapiens (human)
transcription by RNA polymerase IIPoly [ADP-ribose] polymerase 1Homo sapiens (human)
apoptotic processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
DNA damage responsePoly [ADP-ribose] polymerase 1Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayPoly [ADP-ribose] polymerase 1Homo sapiens (human)
response to gamma radiationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of cardiac muscle hypertrophyPoly [ADP-ribose] polymerase 1Homo sapiens (human)
carbohydrate biosynthetic processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein autoprocessingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
signal transduction involved in regulation of gene expressionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
macrophage differentiationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
DNA ADP-ribosylationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of DNA-templated transcription, elongationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to insulin stimulusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of intracellular estrogen receptor signaling pathwayPoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of transcription elongation by RNA polymerase IIPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to UVPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
innate immune responsePoly [ADP-ribose] polymerase 1Homo sapiens (human)
regulation of circadian sleep/wake cycle, non-REM sleepPoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of innate immune responsePoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIPoly [ADP-ribose] polymerase 1Homo sapiens (human)
decidualizationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
regulation of catalytic activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of mitochondrial depolarizationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of SMAD protein signal transductionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of necroptotic processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein poly-ADP-ribosylationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein auto-ADP-ribosylationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein localization to chromatinPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to zinc ionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
replication fork reversalPoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of cGAS/STING signaling pathwayPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of protein localization to nucleusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathwayPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of single strand break repairPoly [ADP-ribose] polymerase 1Homo sapiens (human)
response to aldosteronePoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of adipose tissue developmentPoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of telomere maintenance via telomere lengtheningPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to amyloid-betaPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of myofibroblast differentiationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
regulation of base-excision repairPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of double-strand break repair via homologous recombinationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to nerve growth factor stimulusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
ATP generation from poly-ADP-D-ribosePoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of ATP biosynthetic processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of gene expressionTissue factorHomo sapiens (human)
positive regulation of interleukin-8 productionTissue factorHomo sapiens (human)
positive regulation of endothelial cell proliferationTissue factorHomo sapiens (human)
activation of plasma proteins involved in acute inflammatory responseTissue factorHomo sapiens (human)
activation of blood coagulation via clotting cascadeTissue factorHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processTissue factorHomo sapiens (human)
blood coagulationTissue factorHomo sapiens (human)
positive regulation of platelet-derived growth factor receptor signaling pathwayTissue factorHomo sapiens (human)
protein processingTissue factorHomo sapiens (human)
positive regulation of cell migrationTissue factorHomo sapiens (human)
positive regulation of TOR signalingTissue factorHomo sapiens (human)
positive regulation of angiogenesisTissue factorHomo sapiens (human)
positive regulation of positive chemotaxisTissue factorHomo sapiens (human)
cytokine-mediated signaling pathwayTissue factorHomo sapiens (human)
nicotinamide metabolic processNicotinamide N-methyltransferaseHomo sapiens (human)
response to xenobiotic stimulusNicotinamide N-methyltransferaseHomo sapiens (human)
response to organonitrogen compoundNicotinamide N-methyltransferaseHomo sapiens (human)
animal organ regenerationNicotinamide N-methyltransferaseHomo sapiens (human)
methylationNicotinamide N-methyltransferaseHomo sapiens (human)
NAD biosynthesis via nicotinamide riboside salvage pathwayNicotinamide N-methyltransferaseHomo sapiens (human)
positive regulation of gluconeogenesisNicotinamide N-methyltransferaseHomo sapiens (human)
positive regulation of protein deacetylationNicotinamide N-methyltransferaseHomo sapiens (human)
carbohydrate metabolic processPoly(ADP-ribose) glycohydrolaseHomo sapiens (human)
base-excision repair, gap-fillingPoly(ADP-ribose) glycohydrolaseHomo sapiens (human)
ATP generation from poly-ADP-D-ribosePoly(ADP-ribose) glycohydrolaseHomo sapiens (human)
nucleotide-sugar metabolic processPoly(ADP-ribose) glycohydrolaseHomo sapiens (human)
regulation of DNA repairPoly(ADP-ribose) glycohydrolaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (40)

Processvia Protein(s)Taxonomy
serine-type endopeptidase activityCoagulation factor VIIHomo sapiens (human)
signaling receptor bindingCoagulation factor VIIHomo sapiens (human)
calcium ion bindingCoagulation factor VIIHomo sapiens (human)
protein bindingCoagulation factor VIIHomo sapiens (human)
serine-type peptidase activityCoagulation factor VIIHomo sapiens (human)
DNA bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
chromatin bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
damaged DNA bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
RNA bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
zinc ion bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleotidyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
enzyme bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein kinase bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nuclear estrogen receptor bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleosome bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
ubiquitin protein ligase bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
identical protein bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein homodimerization activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
histone deacetylase bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
R-SMAD bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD DNA ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
transcription regulator activator activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-protein-serine ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+- protein-aspartate ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-protein-glutamate ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-protein-tyrosine ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-protein-histidine ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-histone H2BS6 serine ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-histone H3S10 serine ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-histone H2BE35 glutamate ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
serine-type endopeptidase activityTissue factorHomo sapiens (human)
protease bindingTissue factorHomo sapiens (human)
protein bindingTissue factorHomo sapiens (human)
phospholipid bindingTissue factorHomo sapiens (human)
cytokine receptor activityTissue factorHomo sapiens (human)
nicotinamide N-methyltransferase activityNicotinamide N-methyltransferaseHomo sapiens (human)
pyridine N-methyltransferase activityNicotinamide N-methyltransferaseHomo sapiens (human)
poly(ADP-ribose) glycohydrolase activityPoly(ADP-ribose) glycohydrolaseHomo sapiens (human)
protein bindingPoly(ADP-ribose) glycohydrolaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (28)

Processvia Protein(s)Taxonomy
extracellular regionCoagulation factor VIIHomo sapiens (human)
endoplasmic reticulum lumenCoagulation factor VIIHomo sapiens (human)
Golgi lumenCoagulation factor VIIHomo sapiens (human)
plasma membraneCoagulation factor VIIHomo sapiens (human)
vesicleCoagulation factor VIIHomo sapiens (human)
collagen-containing extracellular matrixCoagulation factor VIIHomo sapiens (human)
serine-type peptidase complexCoagulation factor VIIHomo sapiens (human)
extracellular spaceCoagulation factor VIIHomo sapiens (human)
nucleusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cytosolPoly [ADP-ribose] polymerase 1Homo sapiens (human)
site of double-strand breakPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nuclear replication forkPoly [ADP-ribose] polymerase 1Homo sapiens (human)
site of DNA damagePoly [ADP-ribose] polymerase 1Homo sapiens (human)
chromosome, telomeric regionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nuclear envelopePoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleoplasmPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleolusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
mitochondrionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
membranePoly [ADP-ribose] polymerase 1Homo sapiens (human)
nuclear bodyPoly [ADP-ribose] polymerase 1Homo sapiens (human)
site of double-strand breakPoly [ADP-ribose] polymerase 1Homo sapiens (human)
site of DNA damagePoly [ADP-ribose] polymerase 1Homo sapiens (human)
chromatinPoly [ADP-ribose] polymerase 1Homo sapiens (human)
transcription regulator complexPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein-containing complexPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein-DNA complexPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleolusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
extracellular spaceTissue factorHomo sapiens (human)
plasma membraneTissue factorHomo sapiens (human)
external side of plasma membraneTissue factorHomo sapiens (human)
cell surfaceTissue factorHomo sapiens (human)
membraneTissue factorHomo sapiens (human)
collagen-containing extracellular matrixTissue factorHomo sapiens (human)
serine-type peptidase complexTissue factorHomo sapiens (human)
plasma membraneTissue factorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
cytosolNicotinamide N-methyltransferaseHomo sapiens (human)
cytosolNicotinamide N-methyltransferaseHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
nucleoplasmPoly(ADP-ribose) glycohydrolaseHomo sapiens (human)
mitochondrial matrixPoly(ADP-ribose) glycohydrolaseHomo sapiens (human)
cytosolPoly(ADP-ribose) glycohydrolaseHomo sapiens (human)
nuclear bodyPoly(ADP-ribose) glycohydrolaseHomo sapiens (human)
nucleusPoly(ADP-ribose) glycohydrolaseHomo sapiens (human)
nucleusPoly(ADP-ribose) glycohydrolaseHomo sapiens (human)
cytoplasmPoly(ADP-ribose) glycohydrolaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (67)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID644414Lipophilicity, log D of the compound in octanol-water at pH 7.4 by reverse-phase HPLC analysis2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).
AID1527765Inhibition of full-length human N-terminal TEV cleavage site NNMT (1 to 270 residues) expressed in Escherichia coli BL21-CodonPlus(DE3)-RIPL cells using nicotinamide as substrate preincubated for 10 mins in presence of AdoMet followed by substrate additio2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Novel Propargyl-Linked Bisubstrate Analogues as Tight-Binding Inhibitors for Nicotinamide
AID19262Aqueous solubility2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Prediction of drug solubility from Monte Carlo simulations.
AID406064Inhibition of Mycobacterium tuberculosis fatty acid synthase 1 expressed in Mycobacterium smegmatis mc2 2700 assessed as NADPH oxidation upto 100 mM by spectrophotometry2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs.
AID1245191Cytoprotective activity against H2O2-induced cell damage in rat H9c2 cells at 160 uM incubated for 1 hr before H2O2 challenge for 5 hrs by CCK8 assay2015Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18
Design, Synthesis, and Cardioprotective Effects of N-Mercapto-Based Hydrogen Sulfide Donors.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID19254Partition coefficient of compound was measured in heptane/water system1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations.
AID28957Partition coefficient (logP)2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Rational determination of transfer free energies of small drugs across the water-oil interface.
AID610963Inhibition of PARP in human SCC25 cells assessed as inhibition of MNNG-induced NAD(H) depletion at 1 mM preincubated for 5 mins before MNNG challenge measured after 30 mins2011Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15
Discovery and structure-activity relationships of modified salicylanilides as cell permeable inhibitors of poly(ADP-ribose) glycohydrolase (PARG).
AID23251Partition coefficient (logP)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID610957Inhibition of PARP-1 using [32P]-NAD+ after 15 mins2011Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15
Discovery and structure-activity relationships of modified salicylanilides as cell permeable inhibitors of poly(ADP-ribose) glycohydrolase (PARG).
AID19255Partition coefficient (logP)1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations.
AID162395Inhibitory activity against Poly (ADP-ribose) polymerase 12003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Design and synthesis of poly ADP-ribose polymerase-1 inhibitors. 2. Biological evaluation of aza-5[H]-phenanthridin-6-ones as potent, aqueous-soluble compounds for the treatment of ischemic injuries.
AID23256Partition coefficient (logP) (hexane)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID1201284Inhibition of human soluble tissue factor/factor VIIa expressed in Origami B (DE3) using D-Ile-Pro-Arg-pNA as substrate after 30 mins by spectrophotometric analysis2015Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6
Discovery of novel P1 groups for coagulation factor VIIa inhibition using fragment-based screening.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID610964Inhibition of PARG in human SCC25 cells assessed as inhibition of MNNG-induced poly(ADP-ribose) formation at 1 mM after 20 mins by chemiluminescent ELISA2011Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15
Discovery and structure-activity relationships of modified salicylanilides as cell permeable inhibitors of poly(ADP-ribose) glycohydrolase (PARG).
AID154621The compound was tested for poly(ADP-ribose)-polymerase (PARP) inhibition2001Journal of medicinal chemistry, Nov-08, Volume: 44, Issue:23
Modeling of poly(ADP-ribose)polymerase (PARP) inhibitors. Docking of ligands and quantitative structure-activity relationship analysis.
AID1134000Inhibition of chymotrypsin (unknown origin)1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Quantitative structure-activity relationships of chymotrypsin. On the predictive value of correlation equations.
AID23253Partition coefficient (logP) (carbon tetrachloride)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID23252Partition coefficient (logP) (benzene)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID23254Partition coefficient (logP) (chloroform)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID1134599CHCl3-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID1325941Inhibition of recombinant human factor-7a/TF using S2288 as substrate measured after 60 mins2016ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors.
AID610958Inhibition of PARG using [alpha-32P]ADP-ribose polymers after 5 mins by TRAP assay2011Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15
Discovery and structure-activity relationships of modified salicylanilides as cell permeable inhibitors of poly(ADP-ribose) glycohydrolase (PARG).
AID1204002Inhibition of PARP1 (unknown origin) at 2.8 uM2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
Design, synthesis and biological evaluation of pyridazino[3,4,5-de]quinazolin-3(2H)-one as a new class of PARP-1 inhibitors.
AID23255Partition coefficient (logP) (ether)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID1134600Octanol-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID28956Partition coefficient (logP) (dodecane)2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Rational determination of transfer free energies of small drugs across the water-oil interface.
AID15680Partition coefficient (logP)1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations.
AID1136510Inhibition of alcohol dehydrogenase (unknown origin) assessed as dissociation constant for the complex of enzyme and DPNH1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
A manual method for applying the Hansch approach to drug design.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (502)

TimeframeStudies, This Drug (%)All Drugs %
pre-199069 (13.75)18.7374
1990's87 (17.33)18.2507
2000's92 (18.33)29.6817
2010's194 (38.65)24.3611
2020's60 (11.95)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 70.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index70.86 (24.57)
Research Supply Index6.25 (2.92)
Research Growth Index4.81 (4.65)
Search Engine Demand Index123.31 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (70.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.39%)5.53%
Reviews12 (2.34%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other499 (97.27%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]